CEL-SCI (CVM) Competitors $9.87 -0.38 (-3.71%) Closing price 04:00 PM EasternExtended Trading$9.85 -0.02 (-0.24%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CVM vs. NGNE, LFCR, MREO, ACB, RNAC, CADL, MNPR, NMRA, LXEO, and AVIRShould you be buying CEL-SCI stock or one of its competitors? The main competitors of CEL-SCI include Neurogene (NGNE), Lifecore Biomedical (LFCR), Mereo BioPharma Group (MREO), Aurora Cannabis (ACB), Cartesian Therapeutics (RNAC), Candel Therapeutics (CADL), Monopar Therapeutics (MNPR), Neumora Therapeutics (NMRA), Lexeo Therapeutics (LXEO), and Atea Pharmaceuticals (AVIR). These companies are all part of the "pharmaceutical products" industry. CEL-SCI vs. Its Competitors Neurogene Lifecore Biomedical Mereo BioPharma Group Aurora Cannabis Cartesian Therapeutics Candel Therapeutics Monopar Therapeutics Neumora Therapeutics Lexeo Therapeutics Atea Pharmaceuticals Neurogene (NASDAQ:NGNE) and CEL-SCI (NYSE:CVM) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, media sentiment, risk, profitability and institutional ownership. Which has more risk and volatility, NGNE or CVM? Neurogene has a beta of 1.58, indicating that its stock price is 58% more volatile than the S&P 500. Comparatively, CEL-SCI has a beta of 0.54, indicating that its stock price is 46% less volatile than the S&P 500. Do analysts prefer NGNE or CVM? Neurogene currently has a consensus price target of $46.17, indicating a potential upside of 164.57%. Given Neurogene's stronger consensus rating and higher probable upside, equities research analysts clearly believe Neurogene is more favorable than CEL-SCI.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neurogene 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75CEL-SCI 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is NGNE or CVM more profitable? Neurogene's return on equity of -33.33% beat CEL-SCI's return on equity.Company Net Margins Return on Equity Return on Assets NeurogeneN/A -33.33% -30.34% CEL-SCI N/A -238.05%-104.65% Which has higher valuation & earnings, NGNE or CVM? CEL-SCI has lower revenue, but higher earnings than Neurogene. Neurogene is trading at a lower price-to-earnings ratio than CEL-SCI, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeurogene$930K267.75-$75.14M-$4.31-4.05CEL-SCIN/AN/A-$26.92M-$9.77-1.01 Do institutionals & insiders hold more shares of NGNE or CVM? 52.4% of Neurogene shares are owned by institutional investors. Comparatively, 12.1% of CEL-SCI shares are owned by institutional investors. 9.9% of Neurogene shares are owned by company insiders. Comparatively, 9.9% of CEL-SCI shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the media prefer NGNE or CVM? In the previous week, CEL-SCI had 2 more articles in the media than Neurogene. MarketBeat recorded 3 mentions for CEL-SCI and 1 mentions for Neurogene. Neurogene's average media sentiment score of 1.85 beat CEL-SCI's score of 1.54 indicating that Neurogene is being referred to more favorably in the media. Company Overall Sentiment Neurogene Very Positive CEL-SCI Very Positive SummaryNeurogene beats CEL-SCI on 11 of the 14 factors compared between the two stocks. Get CEL-SCI News Delivered to You Automatically Sign up to receive the latest news and ratings for CVM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CVM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CVM vs. The Competition Export to ExcelMetricCEL-SCIBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$67.93M$287.24M$5.74B$21.50BDividend YieldN/AN/A5.69%3.48%P/E Ratio-20.56N/A74.9329.84Price / SalesN/A429.22457.2751.73Price / CashN/A22.4425.8118.13Price / Book65.8010.6513.254.65Net Income-$26.92M-$111.61M$3.29B$999.94M7 Day Performance-4.64%-1.39%0.47%0.79%1 Month Performance13.45%3.88%4.60%4.54%1 Year Performance-74.30%-14.82%73.42%16.77% CEL-SCI Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CVMCEL-SCI1.3473 of 5 stars$9.87-3.7%N/A-73.3%$67.93MN/A-20.5643Positive NewsShort Interest ↓NGNENeurogene1.9043 of 5 stars$19.45-2.5%$46.17+137.4%-54.7%$284.73M$930K-4.5190Positive NewsLFCRLifecore Biomedical1.0354 of 5 stars$7.29-3.2%$8.00+9.7%+45.2%$281.68M$128.87M-5.56690MREOMereo BioPharma Group2.3332 of 5 stars$1.79+1.1%$7.40+313.4%-56.8%$281.43M$10M-25.5740Positive NewsACBAurora Cannabis0.4782 of 5 stars$4.84-1.4%N/A-16.0%$277.19M$246.72M-25.471,130RNACCartesian Therapeutics2.2953 of 5 stars$10.19-4.2%$40.00+292.5%-42.2%$276.66M$38.91M-0.1964Positive NewsCADLCandel Therapeutics2.3923 of 5 stars$5.10+2.0%$20.00+292.2%-31.7%$274.48M$120K-7.3960Positive NewsMNPRMonopar Therapeutics3.3031 of 5 stars$41.48-6.2%$69.57+67.7%+1,175.1%$272.77MN/A-12.4610News CoverageAnalyst ForecastGap UpNMRANeumora Therapeutics2.9078 of 5 stars$1.66-1.2%$7.14+330.3%-86.5%$272.07MN/A-1.06108Positive NewsLXEOLexeo Therapeutics2.6155 of 5 stars$5.25+4.6%$15.33+192.1%-46.4%$271.09M$650K-1.6158Positive NewsAVIRAtea Pharmaceuticals2.0764 of 5 stars$3.25-3.6%$6.00+84.6%-18.9%$267.43MN/A-2.0270Short Interest ↑ Related Companies and Tools Related Companies Neurogene Competitors Lifecore Biomedical Competitors Mereo BioPharma Group Competitors Aurora Cannabis Competitors Cartesian Therapeutics Competitors Candel Therapeutics Competitors Monopar Therapeutics Competitors Neumora Therapeutics Competitors Lexeo Therapeutics Competitors Atea Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CVM) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CEL-SCI Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share CEL-SCI With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
